Alzheimer's Disease clinical trials
331 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
- Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)
- CBD for Individuals at Risk for Alzheimer's Disease
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
- Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease
- Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
- A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
- Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease
- Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
- Novel Brain Stimulation Treatment for Neuropsychiatric Symptoms in Alzheimer's Disease
- Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
- NiteCAPP: Web-based Interventions for Insomnia in Rural Dementia Caregivers
- Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation
- Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
- Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease
- Aβ Dynamics in LLMD
- A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
- A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
- A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
- A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
- Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
- Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
- Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
- Bumetanide in Patients With Alzheimer's Disease
- Music Therapy for Patients With Alzheimer's Disease
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
- Stem Cell Therapy for Early Alzheimer's Disease
- Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
- Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices)
- Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
- Clinical Trial on Agitation in Alzheimer's Dementia
- Repurposing Siponimod for Alzheimer's Disease
- Mindfulness for Cognition in Early-stage Alzheimer's Disease
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
- Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
- Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
- Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease
- Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study
- Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
- The BRAIN App (Phase 2 SBIR)
- Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
- Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients
- Rifaximin SSD in Dementia Trial
- Low-Intensity Focused Ultrasound (LIFU) Neuromodulation
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Alzheimer's Disease” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.